Description

Tesamorelin 10mg — FDA-Approved GHRH Analog Research Compound

Tesamorelin is the only GHRH analog with full FDA approval — it’s the active ingredient in Egrifta, approved for reducing excess abdominal fat in HIV-positive adults receiving antiretroviral therapy. That clinical track record gives researchers a well-documented reference compound that goes well beyond typical research-only peptides.

The pharmacological profile is distinct from other GHRH analogs: a trans-3-hexenoic acid modification at the N-terminus gives tesamorelin greater stability and a longer half-life than unmodified GHRH. Published clinical trials have documented its effects on GH and IGF-1 levels, visceral adipose tissue, and lipid markers — providing research context that most peptides simply don’t have.

For GH axis researchers, tesamorelin offers the rare combination of strong preclinical data, multiple completed Phase III trials, and an established clinical pharmacology record. It’s the highest-documented compound in Brava’s growth hormone category.

Best For: Growth Hormone Axis

For Research Use Only (RUO). Not for human or veterinary use. Not a drug. Not intended to diagnose, treat, cure, or prevent any disease.